There have been multiple reports of thrombocytopenia associated with efalizumab therapy for the treatment of psoriasis. The current recommendations are to check platelet counts monthly for the first 3 months of efalizumab therapy, then every 3 months for the duration of therapy. We report a case of efalizumab-associated thrombocytopenia that occurred between 10 and 16 weeks after therapy was initiated. Based on our case and a review of the existing reports in the literature, we recommend monthly platelet counts during the first 4 months of therapy, then every 3 months for the duration of therapy. In addition, if the total platelet count drops by 50 x 10(9) cells/L or more between any two consecutive counts, we recommend monthly platelet counts be resumed until the count stabilizes. Finally, patients should be educated about and assessed for the signs and symptoms of thrombocytopenia before starting efalizumab therapy and at every follow-up visit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2007.05.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.
J Asthma Allergy
July 2023
Division of Pulmonary, Critical Care and Sleep Medicine, and the Center for Lung Biology, Department of Medicine, University of Washington, Seattle, WA, USA.
Article Synopsis
- Airway hyperresponsiveness (AHR) is a key feature of asthma, and biologic therapies target specific parts of the inflammatory pathway, which can help understand asthma better.
- This review systematically assessed studies from 1997 to 2021 to evaluate the effects of various biologics on AHR, early allergic response (EAR), and late allergic response (LAR) in asthma patients.
- Findings revealed that Omalizumab and Tezepelumab effectively reduced EAR, LAR, and AHR, while other biologics like Mepolizumab and several others showed little to no impact on AHR or allergic responses.*
A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes.
Transpl Int
June 2023
Division of Transplantation, University of California, San Francisco, San Francisco, CA, United States.
Article Synopsis
- Long-term success of beta-cell replacement is hindered by the toxic effects of calcineurin inhibitors (CNI) on beta-cells and kidney function.
- A study was conducted on 10 Type 1 diabetes patients who received islet transplants with either belatacept or efalizumab for immunosuppression, with 70% of them remaining insulin-independent after 10 years.
- Although patients generally maintained their kidney function, those undergoing pancreas-after-islet (PAI) transplants experienced more significant renal impairment due to CNI, and repeat islet transplants did not effectively sustain long-term insulin independence.
Review of natural compounds for potential psoriasis treatment.
Inflammopharmacology
June 2023
Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt.
Article Synopsis
- * Specific immune cells and molecules, like T cells and TNF, play a key role in psoriasis, leading to the development of targeted chemical drugs over the last two decades.
- * However, these drugs can have severe side effects, prompting interest in natural products or plant-based treatments that may provide therapeutic benefits with fewer risks.
Different Treatment Modalities of Oral Lichen Planus-A Narrative Review.
Dent J (Basel)
January 2023
Department of Oral Medicine, School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Article Synopsis
- Oral lichen planus (OLP) is a chronic inflammatory condition affecting the oral mucosa, presenting symptoms that range from asymptomatic reticular form to painful erosive lesions, making eating difficult.
- Treatment primarily focuses on symptom relief, using topical corticosteroids as the first line of therapy, and systemic corticosteroids for persistent cases.
- Due to limited efficacy and side effects of existing treatments, ongoing research is exploring new therapies like tacrolimus, efalizumab, and others, aiming for better safety and effectiveness.
Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
J Neurol Sci
December 2022
Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States of America; West Virginia Clinical and Translational Science Institute, Morgantown, WV, United States of America; School of Medicine, West Virginia University, Morgantown, WV, United States of America; Division of Multiple Sclerosis and Neuroimmunology Department of Neurology, McGovern Medical School (UT Health), University of Texas Health Science Center at Houston, Houston, TX, United States of America. Electronic address:
Progressive multifocal leukoencephalopathy (PML) is a subacute CNS inflammatory disease seen primarily among immunocompromised patients. It is caused by the JC virus (JCV), a polyomavirus that otherwise induces an insidious, latent infection in the general population. This reactivated disease is characterized by cognitive and behavioral changes, language disturbances, motor weakness, or visual deficits.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!